We describe the development of the practical manufacturing of Ensitrelvir, which was
discovered as a SARS-CoV-2 antiviral candidate. Scalable synthetic methods of indazole,
1,2,4-triazole and 1,3,5-triazinone structures were established, and convergent
couplings of these fragments enabled the development of a concise and efficient scale-up
process to Ensitrelvir. In this process, introducing a
meta
-cresolyl
moiety successfully enhanced the stability of intermediates. Compared to the initial
route at the early research and development stage, the overall yield of the longest
linear sequence (6 steps) was improved by approximately 7-fold. Furthermore, 9 out of
the 12 isolated intermediates were crystallized directly from each reaction mixture
without any extractive workup (direct isolation). This led to an efficient and
environmentally friendly manufacturing process that minimizes waste of organic solvents,
reagents, and processing time. This practical process for manufacturing Ensitrelvir
should contribute to protection against COVID-19.